B · Normal
[U.S. biotechnology company Genmab's intraday gains expanded to more than 25%, and its stock price hit a record high] On October 28, biotechnology company Genmab's intraday gains expanded to more than 25%, and its stock price hit a record high; the company announced the latest data from its Petosemtamab Phase III LiGeR-HN1 study, showing that the combination therapy can reduce the risk of death in patients with head and neck squamous cell carcinoma by 50%. Among U.S. biotechnology stocks, Twist Bioscience rose more than 9%, Recursion Pharmaceuticals rose more than 8%, and Moderna rose more than 4%.
Global market intelligence 🕐 2026-10-28 22:56
#Biotechnology #iOS #RNA #Arm #cell #Global market intelligence #U.S. stock trends
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[The date for the tripartite negotiations between Russia, the United States and 10-28 23:41 [WTI crude oil futures price rose 3%] On October 28, WTI crude oil futures price 10-28 23:38 On October 28, the U.S. Treasury Department auctioned two-year floating-rate Tre 10-28 23:34 [Meta’s stock price fell for 5 consecutive days and fell by more than 20% from t 10-28 23:33 On October 28, India’s Adani Group is considering negotiating to acquire VTTI, a 10-28 23:29 [The United Nations General Assembly calls on the United States to end its block 10-28 23:28

Comments

0/500
Captcha (click to refresh)
No comments yet